Evolent Health Inc Class A Common Stock (EVH)
Stock · NYSE · Consumer Discretionary
$4.57as of 10/16/2026
Price chart
Active signals
EVH Signal Track Record
How signals performed across all stocks →What EVH's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | -1.4% | 44% | September 15, 2026 |
| Bollinger Band Breakdown | 28 | -1.9% | 39% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 18 | +5.0% | 61% | October 6, 2026 |
| Bollinger Band Breakout | 18 | -1.3% | 50% | June 26, 2026 |
| Any 20-session window (baseline) | -3.0% | 43% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About EVH
Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated value-based care platform for health plan administration and management. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and lead…
- Sector
- Consumer Discretionary
- Industry
- Other Consumer Services
- Employees
- 4,200
- Website
- www.evolent.com/
Fundamentals
- 1-day range
- $4.76$5.12
- Market cap
- $403.81M
- P/E (trailing)
- —
- P/E (forward)
- 12.06
- EPS (trailing)
- $-4.52
- Dividend yield
- —
- Beta
- 1.03
- Avg. volume
- 2.99M
How Evolent Health Inc Class A Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
Evolent Health Inc Class A Common Stock Competitors
Chosen by industry and closest market cap.
- EVHEvolent Health Inc Class A Common Stock$4.57▼ 6.16%Market cap $403.81MP/E —$2.1$8.3
- GOTUGaotu Techedu Inc. American Depositary Shares$2.64▼ 1.12%Market cap $453.04MP/E —$1.4$3.3
- FCFranklin Covey Company Common Stock$17.95▼ 1.16%Market cap $241.91MP/E 95.06$11.16$26.81
- CSVCarriage Services Inc. Common Stock$36.2▲ 0.19%Market cap $587.28MP/E 12.78$30.11$52.1
- TPVGTriplePoint Venture Growth BDC Corp. Common Stock$4.42▼ 1.78%Market cap $212.33MP/E 4.56$4.39$6.95
- KLCKinderCare Learning Companies Inc. Common Stock$1.77▼ 3.28%Market cap $605.17MP/E —$1.75$6.27
- EVIEVI Industries Inc. Common Stock$19▼ 1.40%Market cap $180.17MP/E 31.65$12.75$29.42
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| EVH Evolent Health Inc Class A Common Stock | $403.81M | — | $4.57 | ▼ 6.16% | $2.1$8.3 |
| GOTU Gaotu Techedu Inc. American Depositary Shares | $453.04M | — | $2.64 | ▼ 1.12% | $1.4$3.3 |
| FC Franklin Covey Company Common Stock | $241.91M | 95.06 | $17.95 | ▼ 1.16% | $11.16$26.81 |
| CSV Carriage Services Inc. Common Stock | $587.28M | 12.78 | $36.2 | ▲ 0.19% | $30.11$52.1 |
| TPVG TriplePoint Venture Growth BDC Corp. Common Stock | $212.33M | 4.56 | $4.42 | ▼ 1.78% | $4.39$6.95 |
| KLC KinderCare Learning Companies Inc. Common Stock | $605.17M | — | $1.77 | ▼ 3.28% | $1.75$6.27 |
| EVI EVI Industries Inc. Common Stock | $180.17M | 31.65 | $19 | ▼ 1.40% | $12.75$29.42 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Evolent To Release Third Quarter 2026 Financial Results on Thursday, November 5, 2026Yahoo · 10/9/2026
- 3 Reasons to Avoid EVH and 1 Stock to Buy InsteadYahoo · 9/21/2026
- TransPerfect Selected by Evolent for Enterprise-Wide Telephonic InterpretationYahoo · 9/21/2026
- Q2 Healthcare Technology for Providers Earnings: Evolent Health (NYSE:EVH) ImpressesYahoo · 9/16/2026
- 1 of Wall Street’s Favorite Stocks for Long-Term Investors and 2 We Find RiskyYahoo · 9/12/2026
Insider Activity
Insider Actions →- McCarthy Daniel Joseph · August 26, 2026 · Sale65.9K @ $5
- Weinberg Jonathan · July 1, 2026 · Tax Withholding2.6K @ $5.74
- Weinberg Jonathan · July 1, 2026 · Grant43.1K
- Blackley Seth · July 1, 2026 · Tax Withholding10.3K @ $5.74
- Blackley Seth · July 1, 2026 · Grant446.1K
- McCarthy Daniel Joseph · July 1, 2026 · Tax Withholding4.6K @ $5.74
- McCarthy Daniel Joseph · July 1, 2026 · Grant302.6K
- Shams Aammaad · July 1, 2026 · Grant28.8K
- Ajayi Toyin · June 4, 2026 · Grant41.1K
- Glass Russell Monroe · June 4, 2026 · Grant41.1K
- Jelinek Richard M · June 4, 2026 · Grant41.1K
- KECK KIM · June 4, 2026 · Grant41.1K
- Springstubb Brendan B · June 4, 2026 · Grant41.1K
- Craig A. Barbarosh · June 4, 2026 · Grant41.1K
- Smith Jill D. · June 4, 2026 · Grant41.1K
Institutional Ownership
March 31, 2026
- Total shares held
- 108.56M
- Total value held
- $242.48M
- Institutional holders
- 186
- Unknown10.89M
- Unknown10.81M
- Unknown9.08M
- Unknown8.15M
- Unknown5.82M
- Unknown5.56M
- Unknown5.43M
- Unknown4.87M
- Unknown2.67M
- Unknown2.65M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Evolent Health Faces Critique, Wins Telephonic Interpretation Contract
Recent coverage highlights two contrasting stories for Evolent Health. A Yahoo piece lists three reasons to avoid the stock, while another reports that TransPerfect was chosen to provide enterprise‑wide telephonic interpretation services for Evolent. The company’s price is near its 52‑week low and below the average analyst target of $5.77, adding context to the mixed sentiment.
Evolent Health Faces Critique, Wins Telephonic Interpretation Contract. Recent coverage highlights two contrasting stories for Evolent Health. A Yahoo piece lists three reasons to avoid the stock, while another reports that TransPerfect was chosen to provide enterprise‑wide telephonic interpretation services for Evolent. The company’s price is near its 52‑week low and below the average analyst target of $5.77, adding context to the mixed sentiment.